
Session Title: #103: Myelodysplastic Syndromes - When and How to Treat?

Session Type: Education Session

Session Date: Friday, May 29

Location: Level 2, West Hall F1

Session Start Time: 1:00 PM - 2:15 PM

To IPSS or Not? That is the Question - A Review of Biology and Classifications in MDS.

John M. Bennett, MD

Too Many Treatments, Too Little Time

Guillermo Garcia-Manero, MD

What do we Talk About When We Talk About Allogeneic Stem Cell Transplant in These Older Patients?

H. Joachim Deeg, MD

Session Title: #57: Leukemia, Myelodysplasia, and Transplantation

Session Type: Poster Discussion

Session Date: Friday, May 29

Location: Level 2, W240A

Session Start Time: 2:00 PM - 6:00 PM

1 #7009-Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with myelodysplastic syndrome (MDS).

Mikkael Sekeres, MD

2 #7010-Efficacy of a novel schedule of decitabine in previously untreated AML, age 60 or older.

William G Blum, MD

3 #7011-Clinical experience with different dosing schedules of decitabine in patients with myelodysplastic syndromes (MDS).

David Steensma, MD

4 #7012-The role of iron chelation activity of wheat grass juice in patients with myelodysplastic syndrome.

Soma Mukhopadhyay, PhD

5 #7013-Age-specific differences in oncogenic pathway deregulation and chemosensitivity in patients with acute myeloid leukemia: Strategies to maximize response to induction chemotherapy.

Arati V Rao, MD

6 #7014-A nine-gene predictor of therapy response in adult Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).

Zhuang Zuo, MD, PhD

7 #7015-Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia (AML).

Fabio P Santos, MD

8 #7016-Use of SNP-array-based karyotyping for cytogenetic prognostication in unclassified cases of myelodysplasia and associated overlap disorders.

Bhavana Bhatnagar, DO

10 #7018-Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML).

Farhad Ravandi Kashani, MD

11 #7019-Randomized phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML).

Robert K Stuart, MD

12 #7020-Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL).

Stefan Faderl, MD

14 #7022-A phase I dose-escalation study of the novel KSP inhibitor ARRY-520 in advanced leukemias.

Zeev Estrov

15 #7023-Combined tumor necrosis factor- α (TNF- α) and interleukin-2 (IL-2) blockade in acute steroid refractory graft-versus-host disease (SR-GVHD) following allogeneic hematopoietic stem cell transplantation (HCT).

Muthalagu Ramanathan, MD

16 #7024-Sibling donor immunization with patient-derived Id-KLH vaccine prior to reduced-intensity allogeneic hematopoietic cell transplantation for multiple myeloma.

Michael Bishop

17 #7025-Effect of antithymocyte globulins (ATG) as part of the myeloablative conditioning (MAC) regimen on the risk of severe graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (allo-SCT) from matched-unrelated donors (MUD).

Mohamad Mohty, MD, PhD

18 #7026-Alternatively spliced truncated BCR-ABL1 protein in CML patients with resistance to kinase inhibitors.

Jean-Marie Bruey

19 #7027-Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs): Data from an ongoing phase II trial.

Meir Wetzler, MD

20 #7028-BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.

Chen-Hsiung Yeh, PhD

21 #7029-Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study.

Hagop Kantarjian, MD

22 #7030-Chronic myeloid leukemia (CML) with e1a2 BCR-ABL fusion transcript type: Analysis of characteristics, outcomes, and prognostic significance.

Dushyant Verma, MD, FACP

23 #7031-Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab in patients (OFAR2) with Richter's syndrome (RS), and relapsed or refractory B-cell chronic lymphocytic leukemia (CLL).

Apostolia M Tsimberidou, MD, PhD

Session Title: #108: Chronic Lymphocytic Leukemia - Scientific and Therapeutic Advances

Session Type: Education Session

Session Date: Friday, May 29

Location: Level 2, West Hall F3

Session Start Time: 2:45 PM - 4:00 PM

Chemoimmunotherapy of CLL -- A New Gold Standard!

Michael J. Keating, MBBS

Wow! CLL Biology is Really Complicated

Thomas J. Kipps, MD, PhD

Attacking the Target in CLL - A Bullseye?

Neil Kay, MD

Session Title: #58: Leukemia, Myelodysplasia, and Transplantation

Session Type: Poster Discussion

Session Date: Friday, May 29

Location: Level 2, West Hall F1

Session Start Time: 5:00 PM - 6:00 PM

Leukemia, Myelodysplasia, and Transplantation

Steven Gore, MD

Leukemia, Myelodysplasia, and Transplantation

Ivana Gojo, MD

1 #7009-Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with myelodysplastic syndrome (MDS).

Mikkael Sekeres, MD

2 #7010-Efficacy of a novel schedule of decitabine in previously untreated AML, age 60 or older.

William G Blum, MD

3 #7011-Clinical experience with different dosing schedules of decitabine in patients with myelodysplastic syndromes (MDS).

David Steensma, MD

4 #7012-The role of iron chelation activity of wheat grass juice in patients with myelodysplastic syndrome.

Soma Mukhopadhyay, PhD

Discussion: Novel Therapies in Myelodysplastic Syndromes: Progress on Many Fronts

Steven Gore, MD

5 #7013-Age-specific differences in oncogenic pathway deregulation and chemosensitivity in patients with acute myeloid leukemia: Strategies to maximize response to induction chemotherapy.

Arati V Rao, MD

6 #7014-A nine-gene predictor of therapy response in adult Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).

Zhuang Zuo, MD, PhD

7 #7015-Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia (AML).

Fabio P Santos, MD

8 #7016-Use of SNP-array-based karyotyping for cytogenetic prognostication in unclassified cases of myelodysplasia and associated overlap disorders.

Bhavana Bhatnagar, DO

Discussion: Can or Should Genetic Alterations in Acute Leukemias Map the

10 #7018-Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML).

Farhad Ravandi Kashani, MD

11 #7019-Randomized phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML).

Robert K Stuart, MD

12 #7020-Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL).

Stefan Faderl, MD

14 #7022-A phase I dose-escalation study of the novel KSP inhibitor ARRY-520 in advanced leukemias.

Zeev Estrov

Discussion: Targeted Drugs and Combinations in Acute Leukemias: How Novel is Novel?

Ivana Gojo, MD

15 #7023-Combined tumor necrosis factor- α (TNF- α) and interleukin-2 (IL-2) blockade in acute steroid refractory graft-versus-host disease (SR-GVHD) following allogeneic hematopoietic stem cell transplantation (HCT).

Muthalagu Ramanathan, MD

16 #7024-Sibling donor immunization with patient-derived Id-KLH vaccine prior to reduced-intensity allogeneic hematopoietic cell transplantation for multiple myeloma.

Michael Bishop

17 #7025-Effect of antithymocyte globulins (ATG) as part of the myeloablative conditioning (MAC) regimen on the risk of severe graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (allo-SCT) from matched-unrelated donors (MUD).

Mohamad Mohty, MD, PhD

Discussion: Novel Immunotherapeutic Approaches for Improving Outcomes Following Allogeneic Stem Cell Transplantation

Claudio Anasetti, MD

18 #7026-Alternatively spliced truncated BCR-ABL1 protein in CML patients with resistance to kinase inhibitors.

Jean-Marie Bruey

19 #7027-Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs): Data from an ongoing phase II trial.

Meir Wetzler, MD

20 #7028-BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.

Chen-Hsiung Yeh, PhD

21 #7029-Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study.

Hagop Kantarjian, MD

22 #7030-Chronic myeloid leukemia (CML) with e1a2 BCR-ABL fusion transcript type: Analysis of characteristics, outcomes, and prognostic significance.

Dushyant Verma, MD, FACP

23 #7031-Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab in patients (OFAR2) with Richter's syndrome (RS), and relapsed or refractory B-cell chronic lymphocytic leukemia (CLL).

Apostolia M Tsimberidou, MD, PhD

Session Title: #88: Leukemia, Myelodysplasia, and Transplantation

Session Type: General Poster Session

Session Date: Saturday, May 30

Location: Level 2, West Hall C

Session Start Time: 8:00 AM - 12:00 PM

K20 #7032-Impact of azacytidine induction chemotherapies on post-transplant outcomes in patients with myelodysplastic syndromes.

Christopher R Cogle, MD

L3 #7033-Long-term outcomes of high-dose therapy using busulfan, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for patients with high-risk or advanced stages of myeloid malignancies.

Seema G Naik, MD

L4 #7034-Usefulness of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in predicting outcomes for adolescents and young adults (AYAs) with hematologic malignancies (HM) undergoing allogeneic stem cell transplant (alloSCT).

William A Wood, MD, MPH

L5 #7035-Allogeneic hematopoietic cell transplant for multiple myeloma: Comparative results of planned therapy versus salvage therapy.

Leyla Shune, MD

L6 #7036-Vancomycin resistant enterococci (VRE) infections in hematopoietic stem cell transplant (HSCT) recipients.

Ashley E Rosko, MD

L7 #7037-Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting.

Marco Bregni, MD

L10 #7038-A phase II randomized study comparing pegfilgrastim (PEG) versus filgrastim (FIL) after high-dose chemotherapy (HDC) and autologous peripheral blood stem cell support (PBSC).

Luca Castagna, MD

L11 #7039-Low risk for symptomatic venous thromboembolic events (vte) during cytokine administration for peripheral blood stem cell mobilization.

Harris V Naina, MD

L12 #7040-Outcomes of autologous bone marrow transplantation in non-Hodgkin's lymphoma patients who failed peripheral blood stem cell mobilization.

Caroline B Sola, MD

L13 #7041-Multiple myeloma: Autologous stem cell transplantation versus conventional chemotherapy-A retrospective age and stage matched analysis.

Aarti Gupta, MBBS

L14 #7042-Outpatient versus inpatient autologous stem cell transplantation for malignant hematologic disorders.

Ardeshir Ghavamzadeh, MD

L15 #7043-Clinical improvement with a novel CD20 mAb, ofatumumab, in fludarabine-refractory chronic lymphocytic leukemia (CLL) also refractory to alemtuzumab or with bulky lymphadenopathy.

Thomas J. Kipps, MD, PhD

L18 #7044-Activity of ofatumumab, a novel CD20 mAb, and prior rituximab exposure in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia (CLL).

William Wierda

L20 #7046-A phase II study of the tolerability and activity of weekly vincristine sulfate liposomes injection (VSLI) in adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second relapse or progressing following two antileukemia treatment lines.

Leonard T Heffner, MD

M1 #7047-A phase II study with CP-4055 in patients with second salvage AML.

Francis J Giles, MD, FRCP, FRC Path

M2 #7048-A phase II study of voreloxin as single agent therapy for elderly patients (pts) with newly diagnosed acute myeloid leukemia (AML).

Michael B Maris, MD

M3 #7049-Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in *BCR-ABL1*-positive acute lymphoblastic leukemia (ALL) patients.

Annalisa Lonetti

M4 #7050-Comorbidity description using the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in elderly de novo poor-risk AML patients (pts) treated with laromustine.

Gary J Schiller, MD

M5 #7051-Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M. D. Anderson Cancer Center (MDACC) experience.

Naveen Pemmaraju, MD

M6 #7052-Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia.

Bruno C Medeiros, MD

M7 #7053-Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib.

Neil James Gallagher, PhD

M10 #7054-Phase I trial of laromustine in combination with infusional ara-C in elderly patients over age 60 with newly diagnosed AML or high-grade MDS.

Ellen K Ritchie, MD

M11 #7055-Pretransplant comorbidity as an outcome predictor in adult patients younger than 60 years of age receiving standard induction chemotherapy for de novo acute myeloid leukemia.

Se Hyung Kim

M12 #7056-Inference of imatinib (IM) effects on leukemic stem cell (SC) compartment via mathematical modeling of IRIS treatment response data.

Dean Bottino, PhD

M13 #7057-Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study.

Philipp D le Coutre, MD

M14 #7058-A phase III study exploring various doses of imatinib (IM) or IM in combination for newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML) patients (pts): Results of an interim analysis of the SPIRIT trial of French CML group.

Franck E Nicolini, MD, PhD

M15 #7059-Occurrence of venothromboembolism (VTE) in patients (pts) with acute lymphocytic leukemia (ALL), Burkitt's leukemia/lymphoma (BL), or lymphoblastic leukemia (LL).

Nhiem V Luong, MPH

M17 #7060-Effects of the Flt3 ITD on response to chemotherapy in a murine model of acute myeloid leukemia.

Timothy S Pardee, MD, PhD

M18 #7061-High-sensitivity detection of M351T, F317L, and F311C BCR-ABL kinase domain mutation in chronic myeloid leukemia patients treated with novel tyrosine kinase inhibitors (TKIs) imatinib and dasatinib.

AB Rashid R Mir, PhD

M19 #7062-Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor(s).

Harry P Erba, MD, PhD

M20 #7063-Effect of nilotinib on the pharmacokinetics and pharmacodynamics of warfarin.

Ophelia Yin, PhD

M21 #7064-Monitoring chronic myeloid leukemia (CML) response to tyrosine kinase inhibitors (TKI) and homoharringtonine (HHT) using peripheral blood (PB) fluorescence in situ hybridization (FISH) and quantitative RT-PCR (Q-PCR): Are bone marrow biopsies still needed?

Hanna J Khoury, MD, PhD, FACP

N1 #7065-Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias.

Keith W Pratz, MD

N2 #7066-Phase I study results of nanomolecular liposomal annamycin in refractory ALL.

Robert C Shepard, MD

N3 #7067-Prevalence and therapeutic relationships of pericardial effusions in patients with leukemia.

Keeran R Sampat, MD

N4 #7068-Phase I study of pemetrexed in patients with relapsed or refractory acute leukemia or lymphoid blast phase chronic myelogenous leukemia.

William Plunkett, PhD

N6 #7070-Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia (AML).

Martha L Arellano, MD

N7 #7071-Does pre-imatinib (IM) fluorescence in situ hybridization (FISH) predict myelosuppression and outcomes in chronic myeloid leukemia (CML)?

Lisa Lima, BS

N10 #7072-Imatinib mesylate experience of young patients with chronic myeloid leukemia in chronic phase—Care to cure.

Dubashi Biswajit

N11 #7073-Etoposide and mitoxantrone in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy with cytarabine and idarubicin.

Wassim M McHayleh, MD

N12 #7074-Molecular responses with nilotinib 800 mg daily as first-line treatment of chronic myeloid leukemia in chronic phase: Results of a phase II trial of the GIMEMA CML WP.

Giovanni Martinelli, MD

N14 #7076-The effects of sildenafil citrate on malignant B-cells in patients with chronic lymphocytic leukemia.

Bradley A McGregor, MD

N15 #7077-Inadequate BCR-ABL monitoring in imatinib-treated patients with chronic myelogenous leukemia.

Eric Stanek, PharmD

N17 #7078-Chronic lymphocytic leukemia (CLL) coexistent with HIV: An increasing association?

Joanna Cole, MD

N18 #7079-Patterns of imatinib resistance mutation analysis in chronic myeloid leukemia (CML) patients on imatinib at the time of loss of response to the drug in Asian Indian subjects.

Kumar Prabhash, MD, MBBS

N20 #7081-A phase II pilot study of valproic acid in relapsed/refractory chronic lymphocytic leukemia.

Prasanth Ganesan, MD

N21 #7082-Prevalence of paroxysmal nocturnal hemoglobinuria (PNH) cells in patients with myelodysplastic syndromes (MDS), aplastic anemia (AA) or other bone marrow failure (BMF) syndromes: Interim results from the EXPLORE trial.

Naomi Galili, MD

P1 #7083-Functional assessment of performance status in patients with myelofibrosis (MF): Utility and feasibility of the 6-minute walk test (6MWT).

Ruben A Mesa, MD

P2 #7084-Persistence of complete molecular remission in chronic myeloid leukemia after imatinib discontinuation: Interim analysis of the STIM trial.

Francois-Xavier Mahon, MD, PhD

P3 #7085-Role of serum erythropoietin, erythropoietin-independent erythroid colony formation, and bone marrow assessment in the diagnosis of polycythemia vera in patients with JAK2 V617F mutation.

Jessica M MacKenzie-Feder, MD

P4 #7086-Comorbidities and prognosis of myelodysplastic syndromes.

Kiran Naqvi, MD

P5 #7087-The pharmacokinetics of azacitidine following subcutaneous treatment in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML).

Eric Laille

P6 #7088-Outcomes following induction chemotherapy in patients with AML arising from MDS: Analysis of prognostic factors.

Celeste M Bello, MD

P7 #7089-Feasibility of hypomethylating therapy in patients with renal insufficiency.

George Nicolas Batty, MD

P10 #7090-Treatment patterns of chronic myelogenous leukemia patients with suboptimal responses to imatinib.

Annie Guérin

P11 #7091-Mortality and hospitalization in myelodysplastic syndromes (MDS) using the SEER-Medicare linked database.

Karla Lindquist

P12 #7092-Adverse events associated with escalating imatinib versus switching to dasatinib in patients with chronic myelogenous leukemia.

Eric Wu, PhD

P13 #7093-Abrogation of tumor necrosis alpha (TNF-alpha) pathway by anti-TNF therapy in hematological malignancies.

Jeyanthi Ramanarayanan, MD

P14 #7094-Patients with secondary myelodysplastic syndromes (MDS) who are enrolled in AVIDA, a longitudinal registry for patients receiving azacitidine (AZA).

David L Grinblatt, MD

P15 #7095-Plerixafor (P) plus G-CSF (G) in previous peripheral blood progenitor cell (HPC) mobilization failures (MF).

Frits Van Rhee, MD, PhD

P17 #7096-Effect of mobilization chemotherapy with cyclophosphamide and etoposide on stem cell collection by lenalidomide.

Giampaolo Talamo, MD

P18 #7097-BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients.

Jeong-Eun Kim, MD

P19 #7098-Lymphocyte reconstitution in multiple myeloma patients after allogeneic G-CSF-mobilized hematopoietic progenitor cells transplantation from HLA-identical siblings.

Massimo Martino, MD

P20 #7099-Comparative efficacy of reduced or standard doses of lenograstim for peripheral blood stem cell mobilization and transplantation: A randomized study in patients undergoing autologous peripheral stem cell transplantation.

Mustafa Ozturk, BSc, MB, ChB, MD

P21 #7100-Plerixafor (AMD3100) in myeloma and lymphoma patients undergoing autologous stem cell transplantation.

Jan S Moreb, MD

Q1 #7101-Analyzing white blood cell subpopulation for quick and simple predictors for autologous stem cell collection.

Yujia Gao

Q2 #7102-Exploratory analysis describing ultrasonic (US) evaluation of spleen size during peripheral blood progenitor cell (PBPC) mobilization by filgrastim in normal donors.

Patrick J Stiff, MD

Q3 #7103-Expansion of umbilical cord blood mesenchymal stem cells.

Rowayda E Peters, PhD

Q4 #7104-Effects of glucocorticoid treatment on the functional capacity of stem cell transplant recipients entering a rehabilitation program.

Janet S Scheetz, MS, FNP

Q5 #7105-The role of prophylactic antimicrobials during autologous stem cell transplantation: A single center experience.

Dok Hyun Yoon, MD

Q6 #7106-Results of autologous transplants for lymphomas from a tertiary cancer center in India.

Nandish kumar Jeevangi, MD

Session Title: #243: Supportive Care Controversies in Hematology: Transfusions, Growth Factors, and Beyond

Session Type: Clinical Problems In Oncology

Session Date: Saturday, May 30

Location: Level 2, W205A

Session Start Time: 8:00 AM - 9:15 AM

Etiology, management, and prevention of transfusion reactions and refractoriness

Neil Blumberg, MD

Risks and benefits of hematopoietic growth factors in leukemias and MDS

Azra Raza, MD

Transfusion-Associated Iron Overload - Implications for Treatment in MDS

Luca Malcovati, MD

Session Title: #221: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Session Type: Special Session

Session Date: Saturday, May 30

Location: Level 2, West Hall D2

Session Start Time: 9:30 AM - 12:00 PM

Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Nancy E. Davidson, MD

Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Richard L. Schilsky, MD

Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Allen S. Lichter, MD

Importance of Genetic Heterogeneity in Curing Adult Acute Leukemia (AL)

Clara D. Bloomfield, MD

Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Session Title: #215: Forum on Reimbursement

Session Type: Special Session

Session Date: Saturday, May 30

Location: Level 2, West Hall E1

Session Start Time: 3:00 PM - 4:15 PM

Forum on Reimbursement

Joseph S. Bailes, MD

Forum on Reimbursement

Terry S. Coleman, JD

Session Title: #227: Pediatric Oncology Award and Lecture

Session Type: Special Session

Session Date: Saturday, May 30

Location: Level 3, W304E

Session Start Time: 3:00 PM - 4:15 PM

Pediatric Oncology Award and Lecture

William E. Evans, PharmD

Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia (ALL)

Mary V. Relling, PharmD

Pediatric Oncology Award and Lecture

Nancy E. Davidson, MD

Session Title: #216: Global Perspective on Prevention and Intervention in Female Malignancies

Session Type: Special Session

Session Date: Saturday, May 30

Location: Level 2, West Hall E1

Session Start Time: 4:45 PM - 6:00 PM

Breast Health Global Initiative

Benjamin O. Anderson, MD

Global Perspective on BRCA Mutation

Allison W. Kurian, MD, MSc

Female Non-smoking Adenocarcinoma of Lung: Confronting a Unique Disease Entity

Tony Mok, MD

What it Takes to Eradicate Cancer of the Cervix: HPV Vaccine

Richard B.S. Roden, PhD

What it Takes to Eradicate Cancer of the Cervix: Screening

Session Title: #16: Highlights of the Day I including Clinical Trials Participation Awards

Session Type: Oral Presentation

Session Date: Sunday, May 31

Location: Level 2, West Hall D2

Session Start Time: 7:30 AM - 9:00 AM

Highlights of the Day I including Clinical Trials Participation Awards

Daniel F. Hayes, MD

Clinical Trials Participation Awards

Richard L. Schilsky, MD

Breast Cancer Local-Regional and Adjuvant Therapy

Lori J. Pierce, MD

Lymphoma

Jonathan W. Friedberg, MD

Melanoma

David F. McDermott, MD

Patient and Survivor Care

Teresa Gilewski, MD

Gastrointestinal (Colorectal) Cancer

John Marshall, MD

Session Title: #106: Chronic Myeloid Leukemia: Where Are We? Where Are We Going?

Session Type: Education Session

Session Date: Sunday, May 31

Location: Level 2, West Hall F3

Session Start Time: 8:00 AM - 9:15 AM

Frontline Therapy with Imatinib Mesylate: Everything You Wanted to Know but were Afraid to Ask

Moshe Talpaz, MD

Monitoring Response and Resistance in CML -- There's too Much Confusion Here

Michael WN Deininger, MD, PhD

When Imatinib Fails, What Else is There?

Jorge E. Cortes, MD

Session Title: #110: Steroids and Childhood Leukemia: Role in Therapy and Toxic Outcomes (e.g., AVN)

Session Type: Education Session

Session Date: Sunday, May 31

Location: Level 3, W304E

Session Start Time: 8:00 AM - 9:15 AM

AVN management in childhood and adolescent leukemia

Leonard A. Mattano, MD

Toxicity of corticosteroid therapy: treatment- and host-related risk factors

Mary V. Relling, PharmD

Biology and surgical therapy of steroid-induced AVN

Wolf R Drescher, MD, PhD

Session Title: #234: Management of Unusual Plasma Cell Dyscrasias (Excluding Myeloma)

Session Type: Clinical Problems In Oncology

Session Date: Sunday, May 31

Location: Level 2, W205A

Session Start Time: 8:00 AM - 9:15 AM

Management of Unusual Plasma Cell Dyscrasias (Excluding Myeloma)

Todd M. Zimmerman, MD

Management of Unusual Plasma Cell Dyscrasias (Excluding Myeloma)

Raymond Comenzo, MD

Management of Unusual Plasma Cell Dyscrasias (Excluding Myeloma)

Angela Dispenzieri, MD

Session Title: #285: ASCO/AACR Joint Session: Personalized Cancer Therapy - Pathways to Progress

Session Type: Special Session

Session Date: Sunday, May 31

Location: Level 2, West Hall D1

Session Start Time: 9:30 AM - 10:45 AM

Welcome and Introduction

Raymond DuBois, MD, PhD

Welcome and Introduction

Richard L. Schilsky, MD

Insulin and IGF-I as therapeutic targets and modifiable metabolic predictors of prognosis

Sonic Hedgehog Pathway

Daniel D. Von Hoff, MD

Personalizing Cancer Therapy - The PI3K/AKT Pathway

Garth Powis, D.Phil

Session Title: #111: Controversies in Stem Cell Transplantation for Childhood Leukemias

Session Type: Education Session

Session Date: Sunday, May 31

Location: Level 3, W304E

Session Start Time: 9:45 AM - 11:00 AM

Indications for transplant in relapsed ALL --early, mid or late?

Stephan A Grupp, MD, PhD

CML treatment in the age of Gleevec, what can pediatricians learn from young adult experience

Sergio Giralt, MD

Controversies in the management of AML and indications for transplant; European vs. US approaches

Ursula Creutzig, MD

Session Title: #220: Training Program Directors' Special Session: How to Be a Program Director

Session Type: Special Session

Session Date: Sunday, May 31

Location: Level 3, Lecture Hall W300

Session Start Time: 10:30 AM - 12:30 PM

Training Program Directors' Special Session: How to Be a Program Director

Timothy Jerome Moynihan, MD

Training Program Directors' Special Session: How to Be a Program Director

Michael P. Kosty, MD, FACP

Training Program Directors' Special Session: How to Be a Program Director

Linda J. Burns, MD

Session Title: #1: Plenary Session including Science of Oncology Award and Lecture

Session Type: Plenary Presentation

Session Date: Sunday, May 31

Location: Level 2, West Hall D2

Session Start Time: 1:00 PM - 4:00 PM

Plenary Session including Science of Oncology Award and Lecture

Richard L. Schilsky, MD

Plenary Session including Science of Oncology Award and Lecture

Everett E. Vokes, MD

Plenary Session including Science of Oncology Award and Lecture

Nancy E. Davidson, MD

Cancer Genomes and their Implications for Understanding and Managing Cancer

Bert Vogelstein, MD

#1-A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials).

Gordon J Rustin, MD

Discussion

Beth Karlan, MD

#2-Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results.

Stephen J Schuster, MD

Discussion

Ronald Levy, MD

Discussion

Merrill J. Egorin, MD

#3-Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple negative breast cancer (TNBC): Results of a randomized phase II trial

Joyce O'Shaughnessy, MD

#LBA4-A phase III trial comparing mFolfox6 to mFolfox6 + bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08

Norman Wolmark, MD

Discussion

To Be Determined

Session Title: #105: Myeloproliferative Neoplasms

Session Type: Education Session

Session Date: Sunday, May 31

Location: Level 2, West Hall F3

Session Start Time: 4:45 PM - 6:00 PM

Update on the Molecular Pathogenesis Of Myeloproliferative Neoplasms.

Ross L. Levine, MD

Diagnosis and Management of Polycythemia Vera and Essential Thrombocythemia

Ayalew Tefferi, MD

New Therapeutic Approaches in Myelofibrosis

Srdan Verstovsek, MD, PhD

Session Title: #223: B.J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology

Session Type: Special Session

Session Date: Sunday, May 31

Location: Level 3, W330A

Session Start Time: 4:45 PM - 6:00 PM

Geriatric Oncology and the Ultimate Personalized Cancer Care

Martine Extermann, MD

B.J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology

Nancy E. Davidson, MD

Session Title: #17: Highlights of the Day II including Partners in Progress Award

Session Type: Oral Presentation

Session Date: Monday, June 1

Location: Level 2, West Hall D2

Session Start Time: 7:30 AM - 9:00 AM

Highlights of the Day II including Partners in Progress Award

Everett E. Vokes, MD

Highlights of the Day II including Partners in Progress Award

Nancy E. Davidson, MD

Partners in Progress Award

Diane Blum, MSW

Genitourinary (Prostate) Cancer

Gynecologic Cancer

Robert L Coleman, MD

Myeloma

Kenneth C Anderson, MD

Head and Neck Cancer

Marshall R. Posner, MD

Lung Cancer - Metastatic

Bruce E. Johnson, MD

Session Title: #173: Therapeutic Options for Multiple Myeloma: Transplant versus Nontransplant

Session Type: Education Session

Session Date: Monday, June 1

Location: Level 2, West Hall F3

Session Start Time: 8:00 AM - 9:15 AM

Non-transplant regimens for treatment of myeloma

Donna Ellen Reece, MD

Autologous and Allogeneic Transplant Management for Multiple Myeloma

Jean L. Harousseau, MD

Personalized care plan for treatment of myeloma

Morie A. Gertz, MD

Session Title: #284: ASCO/American Society of Hematology Symposium: The Best of ASH

Session Type: Special Session

Session Date: Monday, June 1

Location: Level 2, West Hall F5

Session Start Time: 8:00 AM - 9:15 AM

ASCO/American Society of Hematology Symposium: The Best of ASH

Linda J. Burns, MD

ASCO/American Society of Hematology Symposium: The Best of ASH

Richard L. Schilsky, MD

TET2 Is a Novel Tumor Suppressor Gene Inactivated in Myeloproliferative Neoplasms: Identification of a Pre-JAK2 V617F Event

Francois Delhommeau, PharmD, PhD

A Prospective Randomized Study Comparing Rituximab and Dexamethasone vs Dexamethasone Alone in ITP: Results of Final Analysis and Long-Term Follow Up

Francesco Zaja, MD

Non-Myeloablative Hematopoietic Stem Cell Transplantation in Older Patients with AML and MDS: Results from the Center for International Blood and Marrow Transplant Research (CIBMT)

Brian L. McClune, MD

A Randomized Double-Blind Placebo-Controlled Study on Nadroparin for Prophylaxis of Thromboembolic Events in Cancer Patients Receiving Chemotherapy: The PROTECHT Study

Giancarlo Agnelli, MD

Recombinant Human Erythropoiesis Stimulating Agents in Cancer Patients: Individual Patient Data Meta-Analysis on Behalf of the EPO IPD Meta-Analysis Collaborative Group

Julia Bohlius, MD, MScPH

Session Title: #19: Leukemia, Myelodysplasia, and Transplantation

Session Type: Oral Presentation

Session Date: Monday, June 1

Location: Level 2, West Hall F1

Session Start Time: 9:00 AM - 12:00 PM

Leukemia, Myelodysplasia, and Transplantation

Karen Yee, MD

Leukemia, Myelodysplasia, and Transplantation

Olatoyosi Odenike, MD

#7000-*NPM1* mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML).

Heiko Becker, MD

#7001-MicroRNA 181a (*miR-181a*) expression as a prognosticator in cytogenetically normal acute myeloid leukemia (CN AML).

Sebastian Schwind, MD

#7002-Improving the molecular risk classification for younger (<60 years) de novo cytogenetically normal acute myeloid leukemia (CN AML) patients (pts).

Guido Marcucci, MD

#7003-A randomized trial of anthracycline dose intensification during induction of younger patients with acute myeloid leukemia: Results of Eastern Cooperative Oncology Group study E1900.

Hugo F Fernandez, MD

#7004-Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

Elias Jabbour, MD

#7005-Phase Ib/II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in relapsed or refractory AML patients.

Jeffrey E. Lancet, MD

#7006-Single-agent activity of GCS-100, a first-in-class galectin-3 antagonist, in elderly patients with relapsed chronic lymphocytic leukemia.

Finbarr Cotter, MD, FRCP, FRC Path

Discussion: Therapeutic Advances in AML: Making the Best use of Old and New Drugs.

Anthony Goldstone, FRCR

#7007-Dasatinib dose-optimization study in chronic phase chronic myeloid leukemia (CML-CP): Three-year follow-up with dasatinib 100 mg once daily and landmark analysis of cytogenetic response and progression-free survival (PFS).

Richard M Stone, MD

#7008-Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: Data from an ongoing phase II/III trial.

Jorge E. Cortes, MD

Discussion: When Imatinib Fails: The Sky is Not Falling

Charles Alan Schiffer, MD

Session Title: #222: American Cancer Society Award and Lecture

Session Type: Special Session

Session Date: Monday, June 1

Location: Level 3, W304A

Session Start Time: 9:45 AM - 11:00 AM

A Family Based Approach to Primary Prevention of Breast Cancer

Olufunmilayo I. Olopade, MBBS, FACP

American Cancer Society Award and Lecture

Nancy E. Davidson, MD

Session Title: #376: ASCO/Radiological Society of North America Joint Session - Optimize Your Patient's Care: Talk to Your Radiologist

Session Type: Education Session

Session Date: Monday, June 1

Location: Level 4, Valencia Room, W415D

Session Start Time: 11:30 AM - 12:45 PM

Digesting the Alphabet Soup of Neuroradiology: What does it mean to you and your patient?

Srinivasan Mukundan, Jr., MD, PhD

Imaging of abdominopelvic malignancies: What to tell your Radiologist

Fergus V. Coakley, MD

Interventional Radiology: Ablation, Embolization, Tissue Acquisition, Kyphoplasty, and Other Image-Guided Techniques for the Cancer Patient

Stephen B. Solomon, MD

Fostering Communication between Radiologists and Oncologists: Be Bold, Break the Mold

Annick D. Van den Abbeele, MD

ASCO/Radiological Society of North America Joint Session - Optimize Your Patient's Care: Talk to Your Radiologist

Patrick J. Loehrer, MD

Session Title: #107: Acute Lymphocytic Leukemia: What Is New?

Session Type: Education Session

Session Date: Monday, June 1

Location: Level 2, West Hall F3

Session Start Time: 1:15 PM - 2:30 PM

Allogeneic Stem Cell Transplant in ALL: Who and When?

Dieter Hoelzer, MD, PhD

A la Carte Therapy of Specific ALL Subsets

Susan Mary O'Brien, MD

Adolescents and Young Adults is the Treatment Paradigm Changing?

Francoise Huguet, MD

Session Title: #104: Acute Myeloid Leukemia: New Discoveries for Old Problems

Session Type: Education Session

Session Date: Monday, June 1

Location: Level 2, West Hall F3

Session Start Time: 3:00 PM - 4:15 PM

Frontline Treatment of AML: Are We Making Progress?

Jeffrey E. Lancet, MD

AML in Older Patients -- Is Lowering the Intensity the Right Answer?

Gail J. Roboz, MD

Session Title: #218: ASCO/ESMO Symposium: Global Clinical Trials - Challenges and Solutions

Session Type: Special Session

Session Date: Monday, June 1

Location: Level 2, West Hall F5

Session Start Time: 3:00 PM - 4:15 PM

Welcome and Introduction

Jose Baselga, MD

Accrual Challenges and Proposed Solutions in the U.S. and Europe

George W. Sledge, MD

Optimizing Biospecimen Acquisition Across Borders

Fatima Cardoso, MD

Improving International Collaboration and Trial Design in a Flat World

Richard D. Gelber, PhD

Summary and Conclusions: Focus on Solutions

Richard L. Schilsky, MD

Session Title: #217: Molecular Imaging and Cancer Therapy: Focus on Clinical Trials: An ASCO/SNM Joint Education Session

Session Type: Special Session

Session Date: Monday, June 1

Location: Level 4, Valencia Room, W415D

Session Start Time: 4:45 PM - 6:00 PM

Welcome

Richard L. Schilsky, MD

Welcome

Robert W. Atcher, PhD, MBA

Overview of Molecular Imaging Applications to Cancer Clinical Trials

David A. Mankoff, MD, PhD

Imaging the Pharmacodynamics of Cancer Therapy Using Molecular Imaging

Eric Aboagye, PhD

Proliferation Imaging to Measure Therapy Response

Anthony Frank Shields, MD, PhD

Imaging as a Cancer Biomarker - Lessons Learned from Tissue Biomarkers

Daniel F. Hayes, MD

Session Title: #18: Highlights of the Day III

Session Type: Oral Presentation

Session Date: Tuesday, June 2

Location: Level 2, West Hall D1

Session Start Time: 7:30 AM - 9:00 AM

Highlights of the Day III

Michael A. Carducci, MD

Genitourinary Cancer (Non-Prostate)

Primo Lara, MD

Leukemia, Myelodysplasia, and Transplantation

Charles Alan Schiffer, MD

Breast Cancer - Metastatic

Clifford Hudis, MD

Lung Cancer - Local-Regional and Adjuvant Therapy

Antoinette J Wozniak, MD

Sarcoma

Suzanne George, MD

Gastrointestinal (Noncolorectal) Cancer

Andrew H. Ko, MD